Balipodect

Balipodect is a selective phosphodiesterase 10A inhibitor which was under development by Takeda for the treatment of schizophrenia.
It is active in animal models of antipsychotic-like activity, including inhibition of hyperlocomotion induced by the NMDA receptor antagonist dizocilpine or the dopamine releasing agent methamphetamine, inhibition of conditioned avoidance responses, and reversal of prepulse inhibition deficits.
The drug reached phase 2 clinical trials for this indication but its development was discontinued. It was reported to be poorly effective or ineffective for schizophrenia in clinical trials.